Regeneron Pharmaceuticals, Inc.
REGN
$527.78
-$19.89-3.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -18.37% | 0.09% | |||
| Total Other Revenue | -54.35% | 57.09% | |||
| Total Revenue | -20.07% | 1.84% | |||
| Cost of Revenue | -9.40% | 12.19% | |||
| Gross Profit | -31.72% | -7.48% | |||
| SG&A Expenses | -20.10% | 10.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.46% | 11.82% | |||
| Operating Income | -40.76% | -18.03% | |||
| Income Before Tax | -5.54% | -35.83% | |||
| Income Tax Expenses | 138.37% | -73.49% | |||
| Earnings from Continuing Operations | -11.88% | -31.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.88% | -31.55% | |||
| EBIT | -40.76% | -18.03% | |||
| EBITDA | -36.22% | -16.08% | |||
| EPS Basic | -11.13% | -31.23% | |||
| Normalized Basic EPS | -34.68% | -15.23% | |||
| EPS Diluted | -9.91% | -30.07% | |||
| Normalized Diluted EPS | -33.71% | -13.84% | |||
| Average Basic Shares Outstanding | -0.84% | -0.46% | |||
| Average Diluted Shares Outstanding | -2.28% | -2.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||